ProCE Banner Activity

LEAP-004 Update: Lenvatinib Plus Pembrolizumab for Advanced Melanoma Following Progression on a PD-1/PD-L1 Inhibitor

Slideset Download
Conference Coverage
Updated data from the LEAP 004 trial of lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progression on anti–PD-1/PD-L1 therapy resulted in durable responses and no new safety signals.

Released: June 09, 2021

Expiration: June 08, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme